The study of masitinib in patients with multiple sclerosis
The company AB Science is enrolling patients into the clinical trial investigating Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis.
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
The trial is designed to enroll male and female 18 Years to 65 Years.
The study start date is June 28, 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05441488 or https://clinicaltrials.gov/ct2/show/NCT05441488.
